Last reviewed · How we verify
NCT05836194
Evaluation of Diabetic Retinopathy Using Ultra-Widefield Fundus Images Compared With Two-Field Fundus Images
trial in Retinal Diseases in 769 participants. Completed in 30 June 2024.
30 September 2023
Quick facts
| Lead sponsor | Ningbo Eye Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 769 |
| Start date | 1 October 2022 |
| Primary completion | 30 September 2023 |
| Estimated completion | 30 June 2024 |
| Sites | 1 location across China |
Conditions studied
- Retinal Diseases — all drugs for Retinal Diseases →
- Diabetic Retinopathy — all drugs for Diabetic Retinopathy →
- Diabetes Complications — all drugs for Diabetes Complications →
- Diabetes Mellitus — all drugs for Diabetes Mellitus →
Sponsor
Ningbo Eye Hospital
Who can join
18 and older, any sex, with Retinal Diseases or Diabetic Retinopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to compare the accuracy of evaluating diabetic retinopathy using ultra-widefield fundus images versus two-field fundus images. The hypothesis is that screening and grading diabetic retinopathy based on ultra-widefield fundus images may yield higher accuracy compared to the use of two-field fundus images.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A prospective comparison of ultrawide-field and two-field fundus imaging for diabetic retinopathy assessment.
Li Y, Fu C, Xiu L, Zhang L, et al · · 2026 · PMID 41792656 · DOI 10.1186/s12880-026-02260-z
Verify or expand the search:
- PubMed search for NCT05836194
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Retinal Diseases
Currently open trials in the same condition.
- NCT05981950 — Real-world of AI in Diagnosing Retinal Diseases · recruiting
- NCT06717139 — Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD · active not recruiting
- NCT05724641 — Arterial Spin Labeling MRI for Assessing Blood Perfusion in the Human Eye Repeatability Study and Clinical Application · NA · recruiting
Other Ningbo Eye Hospital trials
Trials by the same sponsor.
- NCT07129889 — Auricular Acupressure Reduces Rebound Effects After Discontinuation of Atropine · NA · not yet recruiting
- NCT06567028 — OSPM-Enhanced AI Model to Identify Premalignant and Malignant Ocular Surface Tumors · completed
- NCT05538793 — Deep Learning for the Discrimination Among Different Types of Keratits: a Nationwide Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05836194 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ningbo Eye Hospital
- Last refreshed: 22 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05836194.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing